Why does testosterone matter in women’s health?
Testosterone is produced in women by the adrenal glands and ovaries. It plays a role in libido, muscle protein synthesis, bone density maintenance, energy metabolism, and aspects of cognitive function and mood. Women’s testosterone levels peak in the mid-twenties and decline gradually from there — with a more notable drop during perimenopause and menopause as ovarian production falls.
The result can be a cluster of symptoms that do not respond to estrogen or progesterone replacement alone: low libido, fatigue despite adequate sleep, difficulty building or maintaining muscle, and a diminished sense of drive or wellbeing. These are symptoms with a plausible hormonal basis that labs can help evaluate.
A 2019 global consensus statement signed by major endocrinology, gynecology, and sexual health societies affirmed that testosterone therapy for women with hypoactive sexual desire disorder — reduced libido without an obvious non-hormonal cause — has the strongest evidence base among the indications explored to date.
Who is a candidate for testosterone HRT as a woman?
Testosterone HRT for women is not appropriate for everyone, and candidacy requires a clinician evaluation with labs, not self-assessment. That said, common patterns that prompt a clinician to consider testosterone as part of an HRT protocol include:
- Perimenopausal or menopausal women experiencing low libido, energy, or mood that has not responded to estrogen and progesterone supplementation alone.
- Surgically menopausal women (following oophorectomy) who experience abrupt testosterone decline alongside estrogen drop.
- Pre-menopausal women with documented low testosterone on labs and consistent symptom presentation, though this group requires more careful evaluation given the broader hormonal context.
- Women with adrenal insufficiency where adrenal-source testosterone production is impaired.
Symptoms alone are insufficient for a diagnosis. The same symptom cluster can have thyroid, sleep, mood, metabolic, or other origins. Labs are the necessary starting point — not symptom checklists.
What labs does a clinician measure before prescribing testosterone to women?
A clinician evaluating testosterone HRT for a woman will typically start with a baseline hormone panel that includes total testosterone, free testosterone (the biologically active fraction), DHEA-S (the major adrenal androgen precursor), estradiol, progesterone, and SHBG (sex hormone-binding globulin, which affects how much testosterone is biologically available). A complete metabolic panel, CBC, and often thyroid function are also evaluated.
This panel matters because free testosterone is often more clinically informative than total testosterone. A woman can have normal total testosterone but low free testosterone if SHBG is elevated — a common situation that affects interpretation. Knowing both numbers and the ratio is how a clinician calibrates whether supplementation is appropriate and at what starting dose.
Follow-up labs at 6–12 weeks after starting a protocol are standard. The goal is to confirm that levels have reached physiological range without overshooting — androgenic side effects (acne, hair changes, voice changes) occur at supraphysiological levels that labs can detect and correct before they become an issue.
Testosterone is a normal female hormone — and for women with documented deficiency, candidacy is confirmed by labs, never by symptoms alone.
What delivery methods and doses are used?
There is no FDA-approved testosterone product specifically indicated for women in the United States. Clinicians working in women’s hormone health typically use compounded testosterone — prepared by a licensed 503A compounding pharmacy in the USA from verified bulk drug substances — or off-label formulations. The absence of an FDA-approved women’s product reflects commercial and regulatory history, not a lack of clinical evidence.
Common delivery methods used in compounded protocols include:
- Topical gels or creams applied daily to areas with thin skin (inner forearm, labia, or other sites the clinician specifies). These allow for consistent absorption and relatively predictable levels.
- Subcutaneous pellets implanted by a clinician every 3–5 months, releasing testosterone continuously. This method avoids daily application but requires an in-office procedure and offers less flexibility for dose adjustment.
- Injectable testosterone at low, physiological doses for women. Less common but used in specific clinical contexts.
The right delivery method depends on the patient’s preference, lifestyle, and clinical context. A clinician’s job is to match the method to the individual — not to default to a standard approach across all patients.
Testosterone HRT within a broader hormonal protocol
Testosterone is rarely the only hormone being evaluated. For perimenopausal and menopausal women, a complete hormonal picture typically includes estradiol and progesterone as well. Testosterone supplementation without addressing estrogen and progesterone deficits (if present) often produces incomplete results.
Some women are already on estrogen and progesterone HRT and are exploring testosterone as an addition to address residual symptoms — particularly libido and energy — that have not responded. Others are starting fresh with a full hormone panel and working with a clinician to understand which deficits are most relevant to their presentation.
PepScribe connects patients with licensed clinicians who review labs, medical history, and symptoms before recommending any protocol. The clinical evaluation is the first step — not the after-the-fact formality.
Frequently asked questions
Can women take testosterone as part of hormone replacement therapy?
Yes. Testosterone is produced naturally in women — primarily by the adrenal glands and ovaries — and plays roles in energy, libido, muscle maintenance, and mood. When testosterone levels decline (often during perimenopause and menopause), some women benefit from low-dose testosterone supplementation as part of a broader HRT protocol, under clinician supervision with labs to guide dosing.
What symptoms suggest low testosterone in women?
Symptoms associated with low testosterone in women can include reduced libido, fatigue, difficulty maintaining muscle tone, mood changes, and diminished sense of wellbeing. These symptoms overlap with other hormonal and non-hormonal conditions, so labs are required to confirm the hormonal picture before any supplementation is considered.
What labs are needed before starting testosterone HRT for women?
A clinician will typically evaluate total testosterone, free testosterone, DHEA-S, estradiol, progesterone, and a complete metabolic panel as a baseline. Thyroid function is often checked given symptom overlap. Labs are required before prescribing and are used at follow-up intervals to guide dose adjustments.
Is testosterone FDA-approved for women?
There is currently no FDA-approved testosterone product specifically indicated for women in the United States. Clinicians may prescribe compounded testosterone (prepared by a licensed 503A pharmacy) or use off-label approaches. A licensed clinician will review the relevant evidence, risks, and your individual history before recommending anything.
What doses of testosterone are used for women?
Physiological doses for women are substantially lower than those used in male TRT protocols. Typical starting ranges involve a fraction of the dose used in men. Specific dosing is individualized by the clinician based on labs, symptoms, and response — it is not a one-size-fits-all number.
Are there risks to testosterone therapy for women?
Potential risks include androgenic effects such as acne, hair thinning, or voice changes at doses that exceed physiological range. Cardiovascular and hematologic monitoring may be warranted depending on individual risk factors. A clinician-supervised, labs-guided approach is specifically designed to stay within physiological ranges and catch any drift before it becomes a problem.